American College of Neuropsychopharmacology Inc. Neuropsychopharmacology
subscribe to npp
SEARCH
Advanced search
My Account E-alerts Subscribe Register Help
Journal home
Current Issue
Advance Online Publication
Archive
Online sample issue FREE!
Author index
Keyword index
For authors
Editorial Board
Instructions for authors
Aims and scope
Indexed in
Author queries
Online Submission
Customer Services
Subscription information
Journal prices
Order sample issue
Purchase articles,
reprints & permissions
Advertising
Contact NPG
nature.com
Original Article
Neuropsychopharmacology (2000) 23 528-538.10.1038/sj.npp.1395548

Sulpiride, a D2/D3 Blocker, Reduces Cataplexy but not REM Sleep in Canine Narcolepsy

Mutsumi Okura1,2 MD, Joyce Riehl1 AB, Emmanuel Mignot1 MD, Ph.D and Seiji Nishino1 MD, Ph.D
1Center for Narcolepsy, Stanford Sleep Center, Stanford University School of Medicine, Palo Alto, CA USA
2Laboratory of Molecular Pharmacology, Biosignal Research Center, Kobe University, Kobe, Japan

Correspondence: Dr Seiji Nishino, Center for Narcolepsy, Department of Psychiatry & Behavioral Sciences, 1201 Welch Road, MSLS Building, Rm. P113, Palo Alto, CA 94304-5485. Tel.: 650-723-3724; Fax: 650-498-7761; nishino@leland.stanford.edu

ABSTRACT

Cataplexy, an abnormal manifestation of REM sleep atonia, is currently treated with antidepressants. These medications also reduce physiological REM sleep and induce nocturnal sleep disturbances. Because a recent work on canine narcolepsy suggests that the mechanisms for triggering cataplexy are different from those for REM sleep, we hypothesized that compounds which act specifically on cataplexy, but not on REM sleep, could be developed. Canine studies also suggest that the dopamine D2/D3 receptor mechanism is specifically involved in the regulation of cataplexy, but little evidence suggests that this mechanism is important for REM sleep regulation. We therefore assessed the effects of sulpiride, a commonly used D2/D3 antagonist, on cataplexy and sleep in narcoleptic canines to explore the possible clinical application of D2/D3 antagonists for the treatment of human narcolepsy. Both acute and chronic oral administration of sulpiride (300 mg/dog, 600 mg/dog) significantly reduced cataplexy without noticeable side effects. Interestingly, the anticataplectic dose of sulpiride did not significantly reduce the amount of REM sleep. Sulpiride (and other D2/D3 antagonists) may therefore be an attractive new therapeutic indication in human narcolepsy.

Keywords: Narcolepsy; Cataplexy; Sulpiride; Dopaminergic System; REM sleep
  top go to top
Article Links
Send to a friend Send to a friend
Download PDF Download PDF
Full Text Full Text
 Next Article Next Article
 Previous Article Previous Article
 Table of Contents Table of Contents
Privacy Policy Copyright © 2000 by the American College of Neuropsychopharmacology